Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Clinical trial NCT04723537 · TERMINATED
Trial details
- NCT number
- NCT04723537
- Sponsor
- RedHill Biopharma Limited
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-16
- Primary completion
- 2021-12-28
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.